PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ajnmmiLink to Publisher's site
 
Am J Nucl Med Mol Imaging. 2012; 2(3): 362–385.
Published online 2012 July 10.
PMCID: PMC3477738

False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer

Abstract

Radioiodine whole-body scintigraphy (WBS), which takes advantage of the high avidity of radioiodine in the functioning thyroid tissues, has been used for detection of differentiated thyroid cancer. Radioiodine is a sensitive marker for detection of thyroid cancer; however, radioiodine uptake is not specific for thyroid tissue. It can also be seen in healthy tissue, including thymus, breast, liver, and gastrointestinal tract, or in benign diseases, such as cysts and inflammation, or in a variety of benign and malignant non-thyroidal tumors, which could be mistaken for thyroid cancer. In order to accurately interpret radioiodine scintigraphy results, one must be familiar with the normal physiologic distribution of the tracer and frequently encountered physiologic and pathologic variants of radioiodine uptake. This article will provide a systematic overview of potential false-positive uptake of radioiodine in the whole body and illustrate how such unexpected findings can be appropriately evaluated.

Keywords: Differentiated thyroid cancer, radioiodine, I-131, I-123, whole-body scintigraphy, false-positive, physiologic uptake, pathologic uptake

Introduction

Differentiated thyroid cancer (DTC) is a favorable malignant tumor, and is associated with a lower risk of death, compared with most other malignancies [1]. Radioiodine has been used for more than five decades for diagnosis and treatment of patients with DTC, with reliance on the fact that trapping, organification, and storage of iodine is more prominent in functioning thyroid tissues than other tissues [2,3]. In particular, on the molecular level, enhanced expression of sodium-iodide symporter (NIS) is a key mechanism of radioiodine uptake in functioning thyroid tissues [4-6]. Radioiodine whole-body scintigraphy (WBS) is an integral part of detection of NIS expression in patients suffering from recurrent or metastatic thyroid cancer and in selection of patients who might benefit from radioiodine therapy [7-9]. Precise interpretation of radioiodine WBS can result in avoidance of futile exposure to high-dose radioiodine and lead patients to optimal management of thyroid cancer, as well as other non-thyroidal disease.

A considerable number of cases of unexpected radioiodine uptake have been reported. Although the mechanism is not fully understood, it can be categorized as follows: 1) functional NIS expression (in normal tissues, including thymus, breast, salivary glands, and gastrointestinal tract, or various benign and malignant tumors), 2) metabolism of radioiodinated thyroid hormone, 3) retention of radioiodinated body fluids (saliva, tears, blood, urine, exudate, transudate, gastric and mucosal secretions, etc.) associated with or without structural change, 4) retention and uptake of radioiodine in inflamed tissue, 5) contamination by physiologic secretions, and 6) unknown. The experienced nuclear medicine physician can differentiate malignant from physiologic radioiodine uptake; however, some findings may remain ambiguous. The first step in evaluation of a patient with suspected residual or recurrent thyroid cancer is correlation of normal or abnormal scintigraphic findings with anatomical imaging, available biochemical data, clinical history, and physical examination. The objectives of this article are to describe the mechanism and distribution of radioiodine uptake, list and discuss normal physiologic variants, list and discuss benign and malignant pathologic causes, and suggest interpretative points for use in differential diagnosis of unusual radioiodine uptake in WBS.

Physiology of iodine and the thyroid gland

In order to better understand the physiology of radioiodine uptake, a thorough understanding of the relationship between iodine and the thyroid gland is important. Iodine is an element with a high atomic number, 53, and is an essential component of hormones produced by the thyroid gland [10]. The recommended daily intake of iodine is 150 μg. Absorption of almost all ingested iodine (>90%) from occurs rapidly; it is distributed in the extracellular iodine pool, which it leaves via transport into the thyroid gland or by renal excretion (Figure 1) [10,11]. In its organic form, iodine is converted mostly to iodide prior to absorption. Exchange of plasma iodide with iodide in red blood cells occurs rapidly, whereas exchange of iodide between extracellular compartments occurs both rapidly and slowly [12]. The kidneys account for more than 90% of iodide excreted from the body. Iodide is also secreted from the blood into the colon; however, the fecal route contributes only about 1% of total iodide clearance from the body [12].

Figure 1
Simplified diagram of the metabolic circuit of iodine. Iodine (I) ingested orally is absorbed from the small bowel into the circulating iodine pool. Approximately one fifth of the iodine in the pool is removed by the thyroid gland and surplus iodine is ...

The cellular mechanism for iodine uptake in thyroid follicular cells is illustrated in Figure 2. NIS on the apical membrane of enterocytes mediates active iodide uptake. This active, energy-requiring process can lead to concentration of iodide in thyrocytes, some 20-40-fold above its level in the circulation [2]. Within the follicular cells, iodide moves toward the apical membrane to enter into the follicular lumen via pendrin, a membrane iodide-chloride cotransporter; it is then oxidized to iodine by peroxidase [10,11]. Thyroid hormones are produced in the thyroid gland by oxidation, organification, and coupling processes, and are finally released into the blood-stream for their action which is an essential for the regulation of a large number of bodily functions, e.g., energy expenditure and metabolic rate [2]. The majority of thyroid hormones in the thyroid gland and plasma are levothyroxine (T4). Most T4 is converted to triiodothyronine (T3), a more metabolically more active form, by deiodination in liver, skeletal muscle, kidney, brain, and other tissues, while the rest is conjugated with sulfate and glucuronide in the liver, excreted in bile, and partially hydrolyzed in the bowel [11]. This could be a possible reason that diffuse hepatic uptake of radioiodine is frequently observed in WBS.

Figure 2
Cellular mechanism for iodine uptake in thyroid follicular cells. This process commences with uptake of iodide from the capillary into follicular cells of the thyroid gland. This process occurs against chemical and electrical gradients via sodium iodide ...

Properties of radioiodines

Iodine-131

I-131 is produced in a nuclear reactor by neutron bombardment of natural tellurium (Te-127) and decays by beta emission to xenon-133 (Xe-133), with a half-life of 8.02 days; it also emits gamma emissions (Table 1). It most often (89% of the time) expends its 971 keV of decay energy by transforming into the stable Xe-131, in two steps; gamma decay rapidly following after beta decay. Beta particles with a maximal energy of 606 keV (89% abundance, others 248-807 keV) and 364 keV gamma rays (81% abundance, others 723 keV) are the primary emissions of I-131 decay. I-131 is administered orally with activities of 1-5 mCi or less. As a result of data suggesting that stunning (decreased uptake of the therapeutic dose of I-131 by the residual functioning thyroid tissue or tumor due to cell death or dysfunction caused by the activity administered for diagnostic imaging) is less likely at the lower activity range, many prefer a range of 1-2 mCi. However, a higher rate of detection of iodine concentrating tissues has been reported with higher dosages [13].

Table 1
Properties of radioiodines (iodine isotopes)

Iodine-123

I-123 is produced in a cyclotron by proton irradiation of enriched Xe-124 in a capsule. Decay of I-123 to Te-123 occurs by electron capture, with a half-life of 13.22 hours and gamma radiation is emitted with predominant energies of 159 keV (the gamma ray primarily used for imaging) and 127 keV. Compared with I-131, I-123 is mainly a gamma emitter with a high counting rate, and provides a higher lesion-to-background signal, thereby improving the sensitivity and quality of imaging. With the same administered activity, I-123 delivers an absorbed radiation dose that is approximately one-fifth that of I-131 to the thyroid tissue, thereby lessening the likelihood of stunning from imaging. I-123 is administered orally with activities of 0.4-5.0 mCi, which may allow avoidance of stunning [13,14].

Iodine-124

I-124 is a proton-rich isotope of iodine produced in a cyclotron by numerous nuclear reactions; it decays to Te-124 with a half-life of 4.18 days. Its modes of decay include: 74.4% electron capture and 25.6% positron emission. It emits gamma radiation with energies of 511 and 602 keV [15]. I-124 is administered intravenously with activities of 0.5-2.0 mCi for detection of metastatic lesions or assessment of the radiation dose related to I-131 therapy. Compared to radioiodine gamma scintigraphy, significantly greater sensitivity and spatial resolution can be achieved using I-124 positron emission tomography, leading to improved detection of residual or recurrent thyroid cancer. And, it can be used for patient-specific radiation dosimetry for radioiodine treatment [16].

Iodine-125

I-125, which is produced in nuclear reactor by neutron capture in irradiated xenon gas (Xe-124), disintegrates by electron capture via the excited level of 35 keV of Te-125 into the ground state of Te-125. It also emits x-rays and Auger electrons, as well as gamma rays. Because of its relatively long half-life (59.39 days), I-125 is preferred for radioimmunoassay or other in vitro assays, and brachytherapy for several solid tumors, including brain tumor, prostate cancer, and head and neck cancer [17-20]. Owing to its low gamma energy, I-125 is not suitable for whole-body gamma camera imaging. Several authors reported regarding the treatment of hyperthyroidism using I-125 in 1970's, however, this was not the case in clinical practice [21].

Physiologic radioiodine uptake

Ectopic thyroid tissue

Ectopic thyroid tissue is the result of a failure of migration of the thyroid gland, which begins at embryonic day 24. An endodermal diverticulum from the median plate of the floor of the pharyngeal gut is formed; this diverticulum then descends in the midline, from the foramen cecum to the final location of the thyroid gland, anteriorly to the pre-trachea and larynx [22]. The innate ability to trap iodine and produce thyroglobulin is shared by ectopic thyroid tissues and normal thyroid tissues, observance of ectopic thyroid tissues in radioiodine WBS is a common false-positive finding [10,23,24]. They are frequently found as a lingual, sublingual thyroid, thyroglossal duct cyst, intratracheal and mediastinal thyroid. They can also be located in both supra- and subdiaphragmatic organs, including lung, heart (struma cordis), adrenal glands, gallbladder, duodenum, ovary (struma ovarii), pancreas and intestine [22]. Simultaneous presentation of two ectopic foci, such as lingual and perihyoid, or lingual and porta hepatis can occur [22,25]. Recognition of the location and nature of ectopic thyroid tissue can minimize misinterpretation as metastatic disease.

Non-thyroidal tissue

Although the abilities to trap iodine and produce thyroglobulin are unique features of thyroid tissues, physiological uptake of radioiodine can also be observed in a variety of non-thyroidal tissues (Figure 3 and and4).4). Two main causes of uptake include functional NIS expression and metabolism related to or the retention of excreted iodine. Expression of NIS in salivary and lacrimal glands, stomach, choroid plexus, ciliary body of the eye, skin, placenta, lactating mammary gland, thymus, and, to a lesser extent, the prostate, ovary, adrenal gland, lung, and heart has been demonstrated [4,6]. Liver is regarded as the major organ for metabolism of radioiodinated thyroglobulin released from functioning thyroid tissues [26]. Retention of radioiodine can occur as a result of structural or functional changes in any part of the body located along the route of radioiodine excretion or blood pooling (Table 2).

Figure 3
Schematic presentation of the locations of physiologic uptake and possible sources of contamination of radioiodine whole-body scan (WBS) [10].
Figure 4
Physiologic uptakes of radioiodine in the whole body; A - planar scintigraphy, B - SPECT/CT. Radioiodine uptakes in nasal secretion (1), parotid gland (2), dental prosthesis (3), remnant thyroglossal duct (4), remnant thyroid tissue (5), liver (6), and ...
Table 2
Physiologic radioiodine uptake

Breast is the one of major organs expressing NIS. Iodine accumulation in the lactating breast has been recognized for 60 years and is now regarded as a usual finding in postpartum patients [27]. Once the NIS gene was cloned and become available for study, expression of NIS on the basolateral membrane of alveolar cells in mammary glands and marked induction during lactation were demonstrated [28,29]. Bakheet et al. [30] conducted an analysis of patterns of radioiodine uptake in lactating breasts on 20 radioiodine scintigraphic images. They identified four patterns of uptake: "full" (most common), "focal", "crescent", and "irregular". Uptake was asymmetric in 60% (left > right in 45%, right > left in 15%), symmetric in 25%, and unilateral in 15% of cases. Recognition of those patterns and clinical history is helpful to interpretation of breast uptake on radioiodine scintigraphy (Figure 5). However, breast uptake that presents with an atypical pattern and/or is clinically unexpected may be interpreted as lung metastases.

Figure 5
Physiologic radioiodine uptake in the breast; A and B - planar scintigraphy, C - SPECT/CT. Unusual uptakes in lower thorax are observed in a nonlactating, 48 year-old female (A, arrows). Following mammography and breast ultrasonography showed negative ...

The significance of radioiodine uptake by the non-lactating breast has also been studied by Hammami et al. [31]. Approximately 6% of all female patients presented with breast uptake unrelated to lactation and the patterns were similar to those observed during breast feeding. Expressible galactorrhea and moderately elevated prolactin levels were observed in 48% and 24% of cases, respectively. According to findings from a recent case report, a 52-year-old female patient presenting with bilateral increased breast uptake was found to have hyperprolactinemia caused by prolactinoma in the pituitary gland [32]. Enhanced NIS expression caused by hyperprolactinemia or individual variations might be a possible mechanism of radioiodine uptake in non-lactating breast.

Hammami et al. [31] suggested the cautious interpretation of radioiodine uptake in the breast when: (a) A history of breastfeeding is not obtained or occurrence of breast uptake without breastfeeding is not acknowledged, (b) The uptake is irregular or unilateral, (c) There is a coexisting lung (or other) metastasis, (d) There is a coexisting elevated thyroglobulin level but an otherwise unremarkable scan.

Thymic radioiodine uptake is not an unusual finding on radioiodine WBS (Figure 6). In a review of 175 patients, thymic uptake was observed in 1.2% (4/325) of diagnostic scans and 1.5% (3/200) of post-treatment scans in six patients [33]. Patients were females between the ages of 22 and 51 years at the time of diagnosis. Wilson et al. observed that physiological thymic uptake was seldom apparent (with one exception; the youngest) on the scan performed at 3-4 days but was clearly observed on the 7-day scan [34]. The pattern of uptake showed either a diffuse or a dumbbell shape. Overall consensus is that thymic uptake tends to become more evident on delayed imaging, with a therapeutic dose, in younger patients, and with less residual or metastatic thyroid tissues [33-39].

Figure 6
Physiologic uptake of radioiodine in the thymus and stomach; A - planar scintigraphy, B - SPECT/CT. An arrowhead-shaped radioiodine uptake in upper mediastinum is noted in a 16 year-old female (A, 1). SPECT/CT revealed it as physiologic uptake in the ...

The mechanism of radioiodine uptake by the thymus is not yet fully understood. Autoradiography performed by Verminglio et al. [35] revealed localization of iodine uptake in the thymus to Hassall’s bodies, which are constituted by epithelial cells resembling keratinocytes. They suggested that this finding reflects the structural similarity between cystic Hassall’s bodies and thyroid follicles. Although a capability of transport and concentration of iodine is weaker in the thymus, compared with that presented in the thyroid gland, the presence of NIS is a proven mechanism of radioiodine uptake in the thymus [40].

Following findings reported by Michigishi et al. [36] will be helpful in differentiating physiologic from malignant mediastinal uptake: (a) uptake that becomes more prominent with repeated treatment, (b) requirement of higher than usual iodine doses in order to visualize the area, (c) a young age, (d) a large thymus on CT, and (e) a low serum thyroglobulin level.

Diffuse hepatic uptake of radioiodine is also a common finding on radioiodine WBS. Several authors have suggested that diffuse uptake of radioiodine by the liver is related to residual thyroid tissue or recurrent or persistent metastasis [26,41]. According to Chung et al. [26], whose study included a large population, because the liver is the major organ for the metabolism of thyroid hormones, this finding was explained by accumulation of radioiodinated thyroid hormones in patients with remnant thyroid tissues. In patients without thyroid remnant, radioiodinated thyroglobulin released from functioning cancer tissue is regarded as the cause of diffuse hepatic uptake of radioiodine.

However, other investigators have stated that diffuse hepatic uptake is a benign finding without clinical importance [42-44]. Tatar et al. [44] reported no significant association between liver uptake and uptake in the thyroid bed, the dose of radioiodine administered for ablation therapy, thyroglobulin levels, age, stage of disease, presence of local or distant metastases, recurrence, or survival. A more recent study of a larger population conducted by Omur et al [42] also revealed no correlation of hepatic uptake with serum thyroglobulin levels, thyroid remnant score, and presence of local or distant metastatic foci. Instead, of particular interest, hepatic uptake showed positive correlation with administered doses of RAI, increased hepatic enzymes, and hepatosteatosis. This finding supports the concept that the presence of multiple metabolic factors is related to diffuse hepatic radioiodine uptake. They suggested that associated changes in lipoproteins and hepatic enzymes might have contributed to increased hepatic uptake in patients with hepatosteatosis. The increase of hepatic enzymes is an indication that delayed action of deiodinase may result in delayed excretion of iodine taken up by hepatocytes and consequent higher liver retention. NIS can also contribute to hepatic radioiodine uptake through mediation of active transport in association with iodine in intrahepatic bile ducts.

Studies of physiologic radioiodine uptake in the liver are summarized in Table 3. Obviously, hepatic visualization tends to occur more frequently in post-therapy scanning, compared with diagnostic scanning, and delayed scanning (8-10 days), compared with early scanning (4-5 days). According to our observations, in studies where an early scan was performed, hepatic visualization appears to be associated with functioning thyroid tissues, whereas it was not in studies performed using a delayed scan (Table 3). This discrepancy may be owing to differences in biological characteristics for trapping or excretion of radioiodine in remnant thyroid tissue, metastatic thyroid tissue, and liver with passage of time.

Table 3
Review of diffuse hepatic uptake of radioiodine

The gestational sac can also be a site of radioiodine accumulation [45]. Although the molecular mechanisms of iodine transport from mother to fetus are not clear, iodide and small amounts of thyroid hormones are transferred through the placenta from mother to fetus. Functional NIS expression in normal human placenta, preferentially in cytotrophoblastic cells, can also be a cause of radioiodine uptake in the gestational sac [46,47].

Physiologic dilatation of the vessel, gut, duct, and ureter, regardless of the presence of obstruction, causes retention of body fluid containing radioiodine. Vascular dilatation of common carotids [48], thoracic aorta [49], and greater saphenous vein [50] have been reported. Displaced blood pool activity associated with pectus excavatum can also be misinterpreted as abnormal radioiodine uptake in the chest [51]. Menstruation history, even in young patients who have not yet reached menarche, should be considered in evaluation of unusual pelvic uptake of radioiodine [52,53]. Retention of tears, saliva, gastric juice, bronchial secretion, bile, intestinal secretion, and urine can be related to a specific disease or clinical situation, such as epiphora, use of aerosol, achalasia, diverticulum, hiatal hernia, gastric volvulus, and ectopic kidney (Figure 7) [48,54-70]. Meckel’s diverticulum has an additional mechanism of radioiodine uptake via NIS, which is originally expressed in gastric mucosa.

Figure 7
Physiologic uptake of radioiodine in the gallbladder and intestines; A - planar scintigraphy, B - SPECT/CT. Focal and segmental uptakes in right upper and left abdomen are noted (A, 1-2). SPECT/CT revealed them as physiologic uptakes unrelated to metastatic ...

Various cystic structures, including the nasolacrimal sac, pleuropericardial, bronchogenic, thymic, breast, hepatic, renal, ovarian, epithelial and sebaceous cysts are also known to show false-positive findings on radioiodine WBS (Figure 8) [71-79]. Entry of radioiodine into cysts occurs via passive diffusion or partially active transport; then, due to the slow exchange of water and chemical elements between the cysts and their surrounding extracellular/extravascular environment, it becomes trapped within the cysts. Although the mechanism is unclear, diffuse radioiodine uptake in bone marrow (bilateral femur and tibia) of patients involved in heavy running activity has also been reported [80].

Figure 8
Physiologic uptake of radioiodine in a simple cyst of the right kidney; A - planar scintigraphy, B - SPECT/CT, C - abdominal CT. Focal tracer uptake is noted at the right side of the abdomen (A, arrows). SPECT/CT (B) and abdominal CT (C) images revealed ...

Contamination by physiological secretion

External contamination by physiological or pathological body secretions or excretions can result in positive radioiodine uptake, which mimics metastatic involvement of DTC (Table 2) [23,24,27,81-97]. Sweat, breast milk, urine, vomitus and nasal, tracheobronchial, lacrimal, salivary secretions and feces contain radioiodine and their contamination on hair, skin, or clothing can be misinterpreted as metastasis of thyroid cancer (Figure 3 and and9).9). Any focus of radioiodine uptake that cannot be explained by physiological or pathological causation must also be suspected as arising from contamination by secretions. Fortunately, contamination is usually easily recognized by its pattern; acquisition of images should be performed after removal of the contamination using decontaminating procedures or removal of stained clothing. However, unusual patterns of contamination might occur and suspicion of the uptake as contamination would be difficult.

Figure 9
Contamination of radioiodine by hair in two patients (A-B and C-D). Unexpected radioiodine uptakes in the outside (A) and on (C) the skull are observed (arrows). On the additional image after rolling up the hair (B and D), the uptakes were moved upward ...

Patients' peculiar physical characteristics or odd habits produce extraordinary patterns of contamination. Careful preparation of patients, including image acquisition in a clean gown after showering, can help to minimize false-positive scanning results due to contamination. Contamination is almost always superficial [23,24], therefore, use of lateral and/or oblique views to give a third dimension to the scan may aid in identification of the contamination. In addition, use of the single photon emission computed tomography (SPECT) image alone or the SPECT image fused with the anatomical image, which provides detailed information on the anatomic location of uptake sites, can be the best way to accurately determine that contamination is the reason for the uptake.

Pathologic radioiodine uptake: non-tumoral disease

Inflammation, which can be caused by any harmful stimuli, such as infection, trauma, or infarction, is the major cause of non-tumoral pathologic radioiodine uptake (Table 4, Figure 10). Inflamed tissues suffer a cascade of biological events, including increased blood flow and capillary permeability. Increased permeability can result in an abundance of cells in tissue or vessels, and stasis of radioiodinated blood can also occur due to an increase in the concentration of cells within blood.

Figure 10
Pathologic uptake of radioiodine in a pulmonary fungus ball; A - planar scintigraphy, B - chest CT. Intense tracer uptake which is considered as solitary pulmonary metastasis is observed in left lower lung field (A, arrows). Following chest CT revealed ...
Table 4
Pathologic uptake unrelated to tumor

Mediator molecules also alter blood vessels in order to permit migration of leukocytes outside of the vessels into the tissue. As part of their bactericidal effect, leukocytes are known to induce iodide organification by means of a myeloperoxidase [98]. Therefore, retention of radioiodine in leukocytes of posttraumatic clots or tissues may also explain various reports of false-positive uptake in sites of inflammation (Figure 11) [99,100].

Figure 11
Pathologic uptake of radioiodine in a superficial scab; A, B, and C - planar scintigraphy, D - photograph. Localized uptake of radioiodine is observed in left lower leg (A and B, arrows). On the lateral view, the uptake is considered to be located in ...

Secretion of mucin containing iodide salts has also been suggested as another possible mechanism of iodine accumulation associated with chronic inflammatory conditions in bronchus, gallbladder, or mucocele [101-106].

Pathologic radioiodine uptake: benign tumor

Although the mechanism is not fully understood, unexpected radioiodine uptakes in diverse benign tumors having different histopathologic natures has been reported (Table 5). Functional NIS expression in parotid tumors, such as Warthin’s tumor or oncocytoma, breast fibroadenoma (Figure 12), ectopic thyroid tissues, such as struma cordis and struma ovarii, other types of ovarian tumors, and teratoma has been suggested [107-115]. Using immunohistochemical staining, Berger et al. [116] demonstrated the presence of high levels of functionally active NIS protein not only in normal breast tissue but also in a benign fibroadenoma. However, in a case of cystic mesothelioma [117], results of immunohistochemical staining did not indicate the presence of NIS expression. It can be speculated that passive diffusion alone might be a mechanism of radioiodine uptake in certain benign tumors.

Figure 12
Pathologic radioiodine uptake in benign fibroadenoma of the breast; A - planar scintigraphy, B - MR mammography. Post-therapy scintigraphy, performed 4 days after a second course of I-131 treatment, showed mild iodine uptake in the former thyroid bed ...
Table 5
Pathologic uptake related to benign tumor

Because meningioma with or without brain edema [118,119], cavernous angioma [120], littoral cell angioma [121], hepatic [122] and vertebral [123,124] hemangiomas, and osteoid osteoma [125] share the property that presents high vascularity, it can also be regarded as another mechanism of radioiodine uptake in a variety of benign tumors.

Pathologic radioiodine uptake: malignant tumor

Radioiodine accumulation has been reported in a variety of cancers, either primary or metastasis, involving the following organs: lung (adenocarcinoma, squamous cell carcinoma, large and small cell carcinoma, and bronchioloalveolar cell carcinoma), breast, stomach and cervix (adenocarcinoma), retroperitoneum (malignant fibrous histiocytoma), and liver and bone (metastatic adenocarcinoma) (Table 6).

Table 6
Pathologic uptake related to non-thyroidal malignant tumor

Expression of NIS is known to occur in more than 80% of breast cancer tissue, although the fraction of tumors that functionally concentrate iodine is likely to be much lower than that in thyroid cancer [29,126]. NIS has also been reported in cancers involving bladder, cervix, oropharynx, colon, lung, pancreas, prostate, skin, stomach, ovary, and endometrium [127]. Of particular interest, absence of NIS was observed in normal lung alveolar tissue, yet positive NIS expression was observed in approximately two thirds of lung adenocarcinomas and squamous cell carcinomas [127]. This suggests that a cellular or subcellular change in iodine affinity as a consequence of malignant transformation leads to accumulation of radioiodine. Tumoral inflammatory response might also play a role in some parts of radioiodine uptake in malignant tumors. Inflammation is a well known microenvironment which is closely related with malignancies [128].

Summaries

Almost 10 years have passed since previous researchers summarized extensively scattered reports in the literature involving cases of false-positive radioiodine uptake during surveillance of patients with DTC [23,24]. Despite the incomparable usefulness of radioiodine scintigraphy, a wide variety of pitfalls, which negate its diagnostic confidence, have been consistently reported. By recognition of the exact localization of radioiodine uptake using emerging hybrid imaging, SPECT/CT, we can reduce the incidence of false-positive interpretation in planar WBS [129]. However, availability of SPECT/CT is still limited and some findings may remain ambiguous. Awareness of the nature and characteristics of radioiodine uptake, as described in Table 7, which provides a summarized review of unusual sites of metastasis and non-thyroidal uptake, might aid in differentiation of thyroidal and non-thyroidal, or benign and malignant uptake of radioiodine in the whole body.

Table 7
Differential diagnosis according to the location and nature of radioiodine uptake

Conclusion

In this review, physiology of the thyroid gland and a systemic overview of potential false-positive uptake of radioiodine in the whole body are provided along with illustrations and cases. By integrating the comprehension of physiology and characteristics of radioiodine uptake outlined in this article with anatomical imaging, biochemical data, and clinical findings, physicians can be more confident in establishing proper management for patients with DTC using radioiodine WBS.

Acknowledgements

This research was financially supported by the Ministry of Knowledge Economy (MKE), Korea Institute for Advancement of Technology (KIAT), and Daegyeong Leading Industry Office through the Leading Industry Development for Economic Region, a Grant from the Nuclear Research & Development Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science & Technology (MEST), and the Brain Korea 21 Project in 2012.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. [PubMed]
2. Wartofsky L, Nostrand DV. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Totowa: Humana Press; 2006.
3. Ahn BC. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics. 2012;2:392–402. [PMC free article] [PubMed]
4. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188–1200. [PubMed]
5. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006;13:797–826. [PubMed]
6. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006;155:495–512. [PubMed]
7. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S492–496. [PubMed]
8. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med. 2006;36:194–205. [PubMed]
9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214. [PubMed]
10. Gholamrezanezhad A. 12 Chapters on Nuclear Medicine. Rijeka: InTech; 2011.
11. Amdur RJ, Mazzaferri EL. Essentials of Thyroid Cancer Management. New York: Springer; 2005.
12. Cavalieri RR. Iodine metabolism and thyroid physiology: current concepts. Thyroid. 1997;7:177–181. [PubMed]
13. Silberstein EB, Alavi A, Balon HR, Becker D, Charkes ND, Clarke SEM, Divgi CR, Donohoe KJ, Delbeke D, Goldsmith SJ, Meier DA, Sarkar SD, Waxman AD. Society of Nuclear Medicine Procedure Guideline for Scintigraphy for Differentiated Papillary and Follicular Thyroid Cancer. 2006.
14. Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med. 2005;46:1473–1480. [PubMed]
15. Rault E, Vandenberghe S, Van Holen R, De Beenhouwer J, Staelens S, Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131) Cancer Biother Radiopharm. 2007;22:423–430. [PubMed]
16. Lubberink M, Abdul Fatah S, Brans B, Hoekstra OS, Teule GJ. The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma. Q J Nucl Med Mol Imaging. 2008;52:30–36. [PubMed]
17. Bodei L, Kassis AI, Adelstein SJ, Mariani G. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother Radiopharm. 2003;18:861–877. [PubMed]
18. Peiffert D. [Insterstitial brachytherapy of localised prostate cancer using iodine 125 permanent implants] . Cancer Radiother. 2005;9:388–393. [PubMed]
19. Jiang P, Jiang Y, Wang JJ, Meng N, Ran W, Qu A, Yang R. Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas. Cancer Biother Radiopharm. 2011;26:753–757. [PubMed]
20. Schwarz SB, Thon N, Nikolajek K, Niyazi M, Tonn JC, Belka C, Kreth FW. Iodine-125 brachytherapy for brain tumours - a review. Radiat Oncol. 2012;7:30. [PMC free article] [PubMed]
21. Iagaru A, McDougall IR. Treatment of thyrotoxicosis. J Nucl Med. 2007;48:379–389. [PubMed]
22. Noussios G, Anagnostis P, Goulis DG, Lappas D, Natsis K. Ectopic thyroid tissue: anatomical, clinical, and surgical implications of a rare entity. Eur J Endocrinol. 2011;165:375–382. [PubMed]
23. Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, Kirkwood ID, Gross MD. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115–132. [PubMed]
24. Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003;24:715–735. [PubMed]
25. Chong A, Jeong SY, Kwon SY, Seo YS, Ha JM, Oh JR, Bom HS, Song HC, Min JJ. Dual lingual thyroid mimicking mono-ectopic thyroid in the anterior view of Tc-99m sodium pertechnetate thyroid scan. Nucl Med Mol Imaging. 2008;42:485–486.
26. Chung JK, Lee YJ, Jeong JM, Lee DS, Lee MC, Cho BY, Koh CS. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191–1195. [PubMed]
27. Honour AJ, Myant NB, Rowlands EN. Secretion of radioiodine in digestive juices and milk in man. Clin Sci. 1952;11:449–462. [PubMed]
28. Cho JY, Leveille R, Kao R, Rousset B, Parlow AF, Burak WE Jr, Mazzaferri EL, Jhiang SM. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab. 2000;85:2936–2943. [PubMed]
29. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestell RG, Carrasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6:871–878. [PubMed]
30. Bakheet SM, Hammami MM. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med. 1994;21:604–608. [PubMed]
31. Hammami MM, Bakheet S. Radioiodine breast uptake in nonbreastfeeding women: clinical and scintigraphic characteristics. J Nucl Med. 1996;37:26–31. [PubMed]
32. Hu LH, Wang SJ, Liu RS. Hyperprolactinemia-related 131I Uptake in Nonlactating Breasts. Clin Nucl Med. 2012;37:e57–58. [PubMed]
33. Davidson J, McDougall IR. How frequently is the thymus seen on whole-body iodine-131 diagnostic and post-treatment scans? Eur J Nucl Med. 2000;27:425–430. [PubMed]
34. Wilson LM, Barrington SF, Morrison ID, Kettle AG, O'Doherty MJ, Coakley AJ. Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med. 1998;25:622–628. [PubMed]
35. Vermiglio F, Baudin E, Travagli JP, Caillou B, Fragu P, Ricard M, Schlumberger M. Iodine concentration by the thymus in thyroid carcinoma. J Nucl Med. 1996;37:1830–1831. [PubMed]
36. Michigishi T, Mizukami Y, Shuke N, Yokoyama K, Noguchi M, Watanabe Y, Matsui O, Aburano T, Tonami N, Hisada K. Visualization of the thymus with therapeutic doses of radioiodine in patients with thyroid cancer. Eur J Nucl Med. 1993;20:75–79. [PubMed]
37. Mello ME, Flamini RC, Corbo R, Mamede M. Radioiodine concentration by the thymus in differentiated thyroid carcinoma: report of five cases. Arq Bras Endocrinol Metabol. 2009;53:874–879. [PubMed]
38. Meller J, Becker W. The human sodiumiodine symporter (NIS) as a key for specific thymic iodine-131 uptake. Eur J Nucl Med. 2000;27:473–474. [PubMed]
39. Connolly LP, Connolly SA. Thymic uptake of radiopharmaceuticals. Clin Nucl Med. 2003;28:648–651. [PubMed]
40. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab. 1998;83:1746–1751. [PubMed]
41. Ziessman HA, Bahar H, Fahey FH, Dubiansky V. Hepatic visualization on iodine-131 whole-body thyroid cancer scans. J Nucl Med. 1987;28:1408–1411. [PubMed]
42. Omur O, Akgun A, Ozcan Z, Sen C, OzkiIic H. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans. Clin Nucl Med. 2009;34:11–14. [PubMed]
43. Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657–660. [PubMed]
44. Tatar FA, Morita E, Ituarte PH, Cavalieri RR, Duh QY, Price DC, Siperstein AE, Clark OH. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718–722. [PubMed]
45. Nishiyama Y, Yamamoto Y, Takahashi K, Nakano S, Satoh K, Takashima H, Ohkawa M, Tanabe M. False-positive iodine-131 whole-body imaging due to gestational sac. Clin Nucl Med. 1998;23:535–536. [PubMed]
46. Di Cosmo C, Fanelli G, Tonacchera M, Ferrarini E, Dimida A, Agretti P, De Marco G, Vitti P, Pinchera A, Bevilacqua G, Naccarato AG, Viacava P. The sodium-iodide symporter expression in placental tissue at different gestational age: an immunohistochemical study. Clin Endocrinol (Oxf) 2006;65:544–548. [PubMed]
47. Mitchell AM, Manley SW, Morris JC, Powell KA, Bergert ER, Mortimer RH. Sodium iodide symporter (NIS) gene expression in human placenta. Placenta. 2001;22:256–258. [PubMed]
48. Giuffrida D, Garofalo MR, Cacciaguerra G, Freni V, Ippolito A, Regalbuto C, Santonocito MG, Belfiore A. False positive 131I total body scan due to an ectasia of the common carotidis. J Endocrinol Invest. 1993;16:207–211. [PubMed]
49. Mena Bares LM, Vallejo Casas JA, Moreno Ortega E, del Real Nunez R, Maza Muret FR, Latre Romero JM. I-131 visualization of thoracic aortic aneurysm after radioiodine administration for thyroid carcinoma. Clin Nucl Med. 2008;33:553–554. [PubMed]
50. Varoglu E, Yildirim M, Bayrakdar R, Kantarci AM, Uslu H. Radioiodine pooling in dilated greater saphenous vein mimicking contamination. Clin Nucl Med. 2003;28:866–868. [PubMed]
51. Muherji S, Ziessman HA, Earll JM, Keyes JW Jr. False-positive iodine-131 whole body scan due to pectus excavatum. Clin Nucl Med. 1988;13:207–208. [PubMed]
52. Mattern M, Staab E. I-131 localization in hematocolpos: a differential diagnosis consideration for pelvic I-131 uptake. Clin Nucl Med. 2007;32:659–660. [PubMed]
53. Rachinsky I, Driedger A. Iodine-131 uptake in a menstruating uterus: value of SPECT/CT in distinguishing benign and metastatic iodine-positive lesions. Thyroid. 2007;17:901–902. [PubMed]
54. Wolff H, Breda DJ, Da Silva N, Hartmann AA. False-positive I-131 deposition in a parotid gland duct ectasia. Clin Nucl Med. 1998;23:257–259. [PubMed]
55. Yuoness S, Rachinsky I, Driedger AA, Belhocine TZ. Differentiated thyroid cancer with epiphora: detection of nasolacrimal duct obstruction on I-131 SPECT/CT. Clin Nucl Med. 2011;36:1149–1152. [PubMed]
56. Shin-Loong TC, Ki W, Sing-Fai L. False-Positive 131I Uptake in Fixed Prosthetic Denture. Clin Nucl Med. 2012;37:e64–66. [PubMed]
57. Kienast O, Hofmann M, Ozer S, Dobrozemsky G, Dudczak R, Kurtaran A. Retention of iodine-131 in respiratory tract in a patient with papillary thyroid carcinoma after radionuclide therapy: a rare false-positive finding. Thyroid. 2003;13:509–510. [PubMed]
58. Nair N, Basu S, Pakhale H. Unusual uptake of radioiodine in the chest in a patient with thyroid carcinoma. Br J Radiol. 2004;77:63–67. [PubMed]
59. Knapska-Kucharska M, Makarewicz J. A case of iodine-131 retention in the esophagus mimicking a mediastinal metastasis in a patient with follicular thyroid carcinoma after gastric volume reduction operation. Clin Nucl Med. 2011;36:817–818. [PubMed]
60. Caplan RH, Gundersen GA, Abellera RM, Kisken WA. Uptake of iodine-131 by a Meckel's diverticulum mimicking metastatic thyroid cancer. Clin Nucl Med. 1987;12:760–762. [PubMed]
61. Bakheet SM, Hammami MM, Powe J. False-positive radioiodine uptake in the abdomen and the pelvis: radioiodine retention in the kidneys and review of the literature. Clin Nucl Med. 1996;21:932–937. [PubMed]
62. You DL, Tzen KY, Chen JF, Kao PF, Tsai MF. False-positive whole-body iodine-131 scan due to intrahepatic duct dilatation. J Nucl Med. 1997;38:1977–1979. [PubMed]
63. Carlisle M, Cortes A, McDougall IR. Uptake of I-131 in the biliary tract: a potential cause of a false-positive result of scintiscan. Clin Nucl Med. 1998;23:524–527. [PubMed]
64. Zucker RJ, Bradley YC, Toney MO, Bridwell RS. Gastric volvulus detected with iodine-131 whole-body imaging. Clin Nucl Med. 2000;25:303–305. [PubMed]
65. Attard M, Marozzi P, Gambino L, Janni F, Salice P, Ficola U, Giuffrida D. False-positive results of an iodine-131 whole-body scan caused by an ectopic kidney. Clin Nucl Med. 2001;26:271–273. [PubMed]
66. Seok JW, Kim SJ, Kim IJ, Kim YS, Kim YK. Normal gallbladder visualization during postablative iodine-131 scan of thyroid cancer. J Korean Med Sci. 2005;20:521–523. [PMC free article] [PubMed]
67. Sioka C, Dimakopoulos N, Kouraklis G, Kotsalou I, Zouboulidis A. False-positive whole-body scan after I-131 therapy in a patient with intestinal scar. Clin Nucl Med. 2006;31:232–233. [PubMed]
68. De la Riva Perez PA, Castro Montano J, Iglesias Jerez R, Lopez Munoz N, Gil Martinez EM, Rodriguez de Quesada B. [Atypical uptake of gallbladder as cause of False-positive iodine-131 in post-surgical removal scanning of thyroid remains] . Rev Esp Med Nucl. 2007;26:52–53. [PubMed]
69. Borkar S, Grewal R, Schoder H. I-131 uptake demonstrated in the appendix on a post-treatment scan in a patient with thyroid cancer. Clin Nucl Med. 2008;33:551–552. [PubMed]
70. Husmann L, Scheffel H, Stumpe K, Schmid S, Alkadhi H, Goerres GW. Pyelocaliceal diverticulum as a rare pitfall in I-131 post-therapy scanning. Clin Nucl Med. 2010;35:443–444. [PubMed]
71. Giuffrida D, Fornito MC, Pellegriti G, Regalbuto C, Vigneri G. False positive 131I total body scan due to bilateral polycystic renal disease. J Endocrinol Invest. 1997;20:342–344. [PubMed]
72. Wen C, Iuanow E, Oates E, Lee SL, Perrone R. Post-therapy iodine-131 localization in unsuspected large renal cyst: possible mechanisms. J Nucl Med. 1998;39:2158–2161. [PubMed]
73. Lungo M, Tenenbaum F, Chaumerliac P, Vons C, Mirat A, Beuzen F, Luton JP, Richard B. [Ovarian endometriosis cyst with iodine 131 uptake : first case of false positive in the follow up for differentiated thyroid carcinoma] . Ann Endocrinol (Paris) 2000;61:147–150. [PubMed]
74. Letaief B, Boughattas S, Guezguez M, Hassine H, Essabbah H. Abdominal uptake of I-131 revealing a renal cyst. Clin Nucl Med. 2001;26:255–256. [PubMed]
75. Okuyama C, Ushijima Y, Kikkawa M, Yamagami T, Nakamura T, Kobayashi K, Hirota T, Nishimura T. False-positive I-131 accumulation in a liver cyst in a patient with thyroid carcinoma. Clin Nucl Med. 2001;26:198–201. [PubMed]
76. Gunawardana DH, Pitman AG, Lichtenstein M. Benign hepatic cyst mimicking a functional thyroid carcinoma metastasis on whole-body I-131 imaging. Clin Nucl Med. 2003;28:527–528. [PubMed]
77. Omur O, Ozbek SS, Akgun A, Yazici B, Mutlukoca N, Ozcan Z. False-positive I-131 accumulation in a hepatic hydatid cyst. Clin Nucl Med. 2007;32:930–932. [PubMed]
78. Kraft O, Sirucek P, Mrhac L, Havel M. I-131 false positive uptake in a huge parapelvic renal cyst. Nucl Med Rev Cent East Eur. 2011;14:36–37. [PubMed]
79. Bural GG, Peel RL, Mountz JM. Benign epithelial cyst mimicking thyroid cancer metastasis: a false-positive finding on post-therapy I-131 scan. Clin Nucl Med. 2012;37:88–90. [PubMed]
80. Bohnen NI, Charron M. Isolated lower extremity I-131 bone marrow uptake in a runner. Clin Nucl Med. 2001;26:163–164. [PubMed]
81. Ash L, Bybel B, Neumann D, Beebe W. The helmet sign: Physiologic radioactive accumulation after 131I therapy--a case report. J Nucl Med Technol. 2004;32:164–165. [PubMed]
82. Bakheet SM, Hammami MM, Hemidan A, Powe JE, Bajaafar F. Radioiodine secretion in tears. J Nucl Med. 1998;39:1452–1454. [PubMed]
83. Beaulieu S, Djang D, Minoshima S. False-positive "necklace sign" on whole-body thyroid cancer survey--a case report. J Nucl Med Technol. 2005;33:42–43. [PubMed]
84. Bhargava P, Choi WS. Artifactual I-131 activity in the hairs after thyroid remnant ablation. Thyroid. 2006;16:1187–1189. [PubMed]
85. Camponovo EJ, Goyer PF, Silverman ED, Kistler AM, Yudt WM. Axillary iodine-131 accumulation due to perspiration. Clin Nucl Med. 1989;14:762–763. [PubMed]
86. Dick C, Mudun A, Alazraki NP. False-positive I-131 images mimicking thyroid cancer metastasis. The nose ring sign. Clin Nucl Med. 1995;20:876–877. [PubMed]
87. Gritters LS, Wissing J, Gross MD, Shapiro B. Extensive salivary contamination due to concurrent use of chewing tobacco during I-131 radioablative therapy. Clin Nucl Med. 1993;18:115–117. [PubMed]
88. Ibis E, Wilson CR, Collier BD, Akansel G, Isitman AT, Yoss RG. Iodine-131 contamination from thyroid cancer patients. J Nucl Med. 1992;33:2110–2115. [PubMed]
89. Joyce WT, Cowan RJ. A potential false-positive posttherapy radioiodine scan secondary to I-131 excretion in perspiration. Clin Nucl Med. 1995;20:368–369. [PubMed]
90. Ozcan Kara P, Sari O, Gedik GK, Kocak I, Kaya B. An interesting contamination artifact appearing in I-(131) whole-body imaging after ablative therapy. Rev Esp Med Nucl. 2011;30:36–37. [PubMed]
91. Ozguven M, Ilgan S, Arslan N, Karacalioglu AO, Yuksel D, Dundar S. Unusual patterns of I-131 contamination. Ann Nucl Med. 2004;18:271–274. [PubMed]
92. Pochis WT, Krasnow AZ, Isitman AT, Cerletty JM, Kir KM, Hellman RS, Collier BD. The radioactive handkerchief sign. A contamination artifact in I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1990;15:491–494. [PubMed]
93. Robinson PS, Barker P, Campbell A, Henson P, Surveyor I, Young PR. Iodine-131 in breast milk following therapy for thyroid carcinoma. J Nucl Med. 1994;35:1797–1801. [PubMed]
94. Roman MR, Larcos G, Devadas M. Lick your lips: a case of salivary contamination after I-131 therapy for thyroid carcinoma. Clin Nucl Med. 2002;27:462. [PubMed]
95. Rubow S, Klopper J. Excretion of radioiodine in human milk following a therapeutic dose of I-131. Eur J Nucl Med. 1988;14:632–633. [PubMed]
96. Schechter D, Krausz Y, Moshe S, Rubinstein R, Chisin R. Radioiodine hot hand sign. Clin Nucl Med. 1998;23:378–379. [PubMed]
97. Zakavi SR, Kakhki VD. Exercise-induced radio-iodine accumulation in scalp and hair during admission of 131I therapy for thyroid cancer. Thyroid. 2006;16:1185–1186. [PubMed]
98. Klebanoff SJ, Hamon CB. Role of myeloperoxidase-mediated antimicrobial systems in intact leukocytes. J Reticuloendothel Soc. 1972;12:170–196. [PubMed]
99. Regalbuto C, Buscema M, Arena S, Vigneri R, Squatrito S, Pezzino V. False-positive findings on (131)I whole-body scans because of posttraumatic superficial scabs. J Nucl Med. 2002;43:207–209. [PubMed]
100. Brucker-Davis F, Reynolds JC, Skarulis MC, Fraker DL, Alexander HR, Weintraub BD, Robbins J. False-positive iodine-131 whole-body scans due to cholecystitis and sebaceous cyst. J Nucl Med. 1996;37:1690–1693. [PubMed]
101. Matheja P, Lerch H, Schmid KW, Kuwert T, Schober O. Frontal sinus mucocele mimicking a metastasis of papillary thyroid carcinoma. J Nucl Med. 1997;38:1022–1024. [PubMed]
102. Duque JJ, Miguel MB, Ruiz E, Castillo L, Claver M, Rubio MJ, Calvo JI, Rodriguez A, Zamora B, Casado C. False-positive I-131 whole-body scan in follicular thyroid carcinoma caused by frontal sinus mucocele. Clin Nucl Med. 2000;25:137–138. [PubMed]
103. Bakheet SM, Hammami MM, Powe J. Radioiodine bronchogram in acute respiratory tract infection. Clin Nucl Med. 1997;22:308–309. [PubMed]
104. Jong I, Taubman K, Schlicht S. Bronchiectasis simulating pulmonary metastases on iodine-131 scintigraphy in well-differentiated thyroid carcinoma. Clin Nucl Med. 2005;30:688–689. [PubMed]
105. Picolos MK, Habra M, Safdar A, Sarlis NJ. Inactive pulmonary tuberculosis mimicking metastasis from papillary thyroid carcinoma in diagnostic radioiodine whole-body scintigraphy. Thyroid. 2005;15:1105–1106. [PubMed]
106. McEwan LM, Fong W. Unusual extrathyroidal iodine accumulation in a post-ablative I-131 scan. Australas Radiol. 2001;45:512–513. [PubMed]
107. Ilgan S, Narin Y, Arslan N, Aksu A, Bayhan H. Warthin's tumor and I-131 body scan. Clin Nucl Med. 1999;24:721–722. [PubMed]
108. Caglar M, Tuncel M, Usubutun A. Increased uptake on I-131 whole-body scintigraphy in Warthin tumor despite false-negative Tc-99m pertechnetate salivary gland scintigraphy. Clin Nucl Med. 2003;28:945–946. [PubMed]
109. Gekeler J, Luers JC, Krohn T, Beutner D. False positive findings in F-18 FDG PET and whole body scans with I-131 in Warthin tumor of the parotid gland. Clin Nucl Med. 2010;35:105–106. [PubMed]
110. Broekhuizen-de Gast H, van Isselt H, Roef M, Lam M. Oncocytoma of the parotid gland causing false-positive result on I-131 whole-body scintigraphy. Clin Nucl Med. 2011;36:701–703. [PubMed]
111. Macdonald W, Armstrong J. Benign struma ovarii in a patient with invasive papillary thyroid cancer: detection with I-131 SPECT-CT. Clin Nucl Med. 2007;32:380–382. [PubMed]
112. Agriantonis DJ, Hall L, Wilson MA. Pitfalls of I-131 whole body scan interpretation: bronchogenic cyst and mucinous cystadenoma. Clin Nucl Med. 2008;33:325–327. [PubMed]
113. Qiu ZL, Xu YH, Song HJ, Luo QY. Unusual (1) (3)(1)I uptake in a benign mucinous cystadenoma of the ovary in a patient with papillary thyroid cancer. Clin Nucl Med. 2010;35:965–966. [PubMed]
114. Flug J, Lameka K, Lee R, Katz DS, Sung WW, Yung E. False-positive I-131 uptake by an ovarian serous cystadenofibroma. Clin Nucl Med. 2012;37:178–180. [PubMed]
115. Rieser GD, Ober KP, Cowan RJ, Cordell AR. Radioiodide imaging of struma cordis. Clin Nucl Med. 1988;13:421–422. [PubMed]
116. Berger F, Unterholzner S, Diebold J, Knesewitsch P, Hahn K, Spitzweg C. Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma. Biochem Biophys Res Commun. 2006;349:1258–1263. [PubMed]
117. de Keizer B, Arsos G, Smit JW, Lam MG, Rinkes IH, Goldschmeding R, van Isselt JW. I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer. Thyroid. 2008;18:369–371. [PubMed]
118. Schmidt M, Scheidhauer K, Urbannek V, Luyken C, Friese M, Voth E, Schicha H. [Metastasizing follicular thyroid carcinoma with intracranial iodine 131 uptake in brain edema due to a frontal meningioma] . Nuklearmedizin. 2000;39:38–39. [PubMed]
119. Sinha P, Conrad GR, Holzhauer M. Incidental detection of a falx meningioma on post-therapy radioiodide whole-body imaging. Clin Nucl Med. 2002;27:916–917. [PubMed]
120. Bulzico D, Vaisman F, Cordeiro de Noronha Pessoa CH, Corbo R. Cavernous angioma mimicking a differentiated thyroid carcinoma brain metastasis. Clin Nucl Med. 2011;36:62–63. [PubMed]
121. Mohan V, Jones RC, Drake AJ 3rd, Daly PL, Shakir KM. Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen. Thyroid. 2005;15:170–175. [PubMed]
122. Karyagar S, Uyanik E, Mulazimoglu M, Karyagar SS. Uptake of (131)I on a post thyroid ablation whole body scan, due to cavernous liver hemangioma, mimicking metastases. Hell J Nucl Med. 2009;12:177–178. [PubMed]
123. Laguna R, Silva F, Vazquez-Selles J, Orduna E, Flores C. Vertebral hemangioma mimicking a metastatic bone lesion in well-differentiated thyroid carcinoma. Clin Nucl Med. 2000;25:611–613. [PubMed]
124. Khan S, Dunn J, Strickland N, Al-Nahhas A. Iodine-123 uptake in vertebral haemangiomas in a patient with papillary thyroid carcinoma. Nucl Med Rev Cent East Eur. 2008;11:30–33. [PubMed]
125. Rachinsky I, Shelef I, Agranovich S, Lantsberg S. Is osteoid osteoma an iodophilic lesion?: pathologically proved osteoid osteoma of nasal bone first seen on whole-body iodine-131 scan. Clin Nucl Med. 2003;28:696–698. [PubMed]
126. Wapnir IL, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, Carrasco N. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004;10:4294–4302. [PubMed]
127. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, Greco RS, Dohan O, Carrasco N. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88:1880–1888. [PubMed]
128. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. [PubMed]
129. Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, Kang SR, Kim DY, Song HC, Bom HS, Min JJ. Comparison of (1)(3)(1)I whole-body imaging, (1)(3)(1)I SPECT/CT, and (1)F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38:1459–1468. [PubMed]
130. Mulazimoglu M, Koca S, Tamam MO, Uyanik E, Ozpacaci T. False-positive findings in post-treatment iodine-131 whole-body scintigraphy in a nasolacrimal sac cyst, confirmed with SPECT/CT and MRI. Clin Nucl Med. 2011;36:805–807. [PubMed]
131. Feuerstein IM, Harbert JC. Hypertrophied thyroid tissue in a thyroglossal duct remnant. Clin Nucl Med. 1986;11:135. [PubMed]
132. Perros P, Mallick UK, Fenwick JD. Radioiodine uptake in normal female breasts and liver of a patient with differentiated thyroid cancer imaged by whole body scanning. Thyroid. 2003;13:511. [PubMed]
133. Welcsh PL, Mankoff DA. Taking up iodide in breast tissue. Nature. 2000;406:688–689. [PubMed]
134. Hsiao E, Huynh T, Mansberg R, Bautovich G, Roach P. Diagnostic I-123 scintigraphy to assess potential breast uptake of I-131 before radioiodine therapy in a postpartum woman with thyroid cancer. Clin Nucl Med. 2004;29:498–501. [PubMed]
135. Sinha A, Bradley KM, Steatham J, Weaver A. Asymmetric breast uptake of radioiodine in a patient with thyroid malignancy: metastases or not? J R Soc Med. 2008;101:319–320. [PMC free article] [PubMed]
136. Lin EC. Iodine-131 uptake in thymic hyperplasia with atypical computed tomographic features. Clin Nucl Med. 2000;25:375. [PubMed]
137. Ozdemir A, Gungor F, Ozugur S, Cubuk M, Boz A, Karayalcin B. Abnormal iodine-131 uptake in the mediastinum caused by achalasia. Clin Nucl Med. 1998;23:706–707. [PubMed]
138. Boulahdour H, Meignan M, Melliere D, Braga F, Galle P. False-positive I-131 scan induced by Zenker's diverticulum. Clin Nucl Med. 1992;17:243–244. [PubMed]
139. Song HC, Kim SM, Heo YJ, Bom HS. Retention of iodine-131 in a thoracic esophageal diverticulum mimicking metastatic thyroid cancer. Clin Nucl Med. 2002;27:896–897. [PubMed]
140. Rashid K, Johns W, Chasse K, Walker M, Gupta SM. Esophageal diverticulum presenting as metastatic thyroid mass on iodine-131 scintigraphy. Clin Nucl Med. 2006;31:405–408. [PubMed]
141. Nguyen BD, Roarke MC. Epiphrenic diverticulum: potential pitfall in thyroid cancer iodine-131 scintigraphy. Clin Nucl Med. 2005;30:631–632. [PubMed]
142. Schuster DM, Alazraki N. Esophageal scarring causing false-positive uptake on I-131 whole-body imaging. Clin Nucl Med. 1998;23:334. [PubMed]
143. Freeman M, Roach P, Robinson B, Shields M. Hiatal hernia in iodine-131 scintigraphy: a potential cause of false-positive midline thoracic uptake. Clin Nucl Med. 2003;28:709–710. [PubMed]
144. Ceylan Gunay E, Erdogan A. Mediastinal radioiodine uptake due to hiatal hernia: a false-positive reason in 131I scan. Rev Esp Med Nucl. 2010;29:95. [PubMed]
145. Francese C, Schlumberger M, Travagli JP, Vera P, Caillou B, Parmentier C. Iodine 131 uptake in a pleuropericardial cyst: case report of a false-positive radioiodine total body scan result in a patient with a thyroid cancer. Eur J Nucl Med. 1991;18:779–780. [PubMed]
146. Lejeune M, Heron C, Tenenbaum F, Sarfati PO, Louvel A, Luton JP, Richard B. [Iodine 131 uptake by a bronchogenic cyst in a patient with differentiated carcinoma of the thyroid gland] . Presse Med. 2000;29:1345–1347. [PubMed]
147. Kayano D, Michigishi T, Ichiyanagi K, Inaki A, Kinuya S. I-131 uptake in a thymic cyst. Clin Nucl Med. 2010;35:438–439. [PubMed]
148. Serafini A, Sfakianakis G, Georgiou M, Morris J. Breast cyst simulating metastases on iodine-131 imaging in thyroid carcinoma. J Nucl Med. 1998;39:1910–1912. [PubMed]
149. Bakheet SM, Hammami MM. False-positive radioiodine whole-body scan in thyroid cancer patients due to unrelated pathology. Clin Nucl Med. 1994;19:325–329. [PubMed]
150. Turoglu HT, Naddaf S, Young I, Abdel-Dayem HM. Infected sebaceous cyst. A cause for false-positive total-body I-123 metastatic survey for thyroid cancer. Clin Nucl Med. 1996;21:887. [PubMed]
151. Kinuya S, Yokoyama K, Michigishi T, Tonami N. I-131 accumulation in folliculitis of the scalp. Clin Nucl Med. 1996;21:807–808. [PubMed]
152. Kolla IS, Alazraki NP, Watts NB. Sialadenitis mimicking metastatic thyroid carcinoma. Clin Nucl Med. 1989;14:564–566. [PubMed]
153. Carlisle MR, McDougall IR. Dramatic parotid uptake of I-131 on a diagnostic whole-body scan. Clin Nucl Med. 2000;25:895–897. [PubMed]
154. Bakheet SM, Hammami MM, Powe J, Larsson S. Radioiodine uptake in the head and neck. Endocr Pract. 2000;6:37–41. [PubMed]
155. Schmidt M, Dietlein M, Schroder U, Schicha H. False-positive uptake of I-131 in a laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid carcinoma. Clin Nucl Med. 2006;31:716–717. [PubMed]
156. Niepomniszcze H, Schere D. How to distinguish between radioiodine accumulation in a laryngocele from a radioiodine-concentrating thyroid remnant after thyroidectomy for papillary carcinoma. Thyroid. 2004;14:867–868. [PubMed]
157. Ong SC, Eng DN, Sundram FX, Chan LL. A novel case of false-positive I-131 whole-body scan in thyroid carcinoma caused by subdural hematoma. Clin Nucl Med. 2004;29:164–166. [PubMed]
158. Ain KB, Shih WJ. False-positive I-131 uptake at a tracheostomy site. Discernment with Tl-201 imaging. Clin Nucl Med. 1994;19:619–621. [PubMed]
159. Vallejo Casas JA, Mena Bares ML, Galvez Moreno MA, Latre Romero JM. [Tracheostomy cannula as a cause of false positive result on the whole-body scan with (131)I in the follow-up of differentiated thyroid cancer] . Rev Esp Med Nucl. 2011;30:384–385. [PubMed]
160. Modoni S, Martino G, Guerra M, Frusciante V. Unusual radioiodine uptake caused by metallic sutures in the skull in a patient with thyroid cancer. Clin Nucl Med. 2000;25:1053–1054. [PubMed]
161. Campenni A, Minutoli F, Pecorella GR, Baldari S. Unusual radioiodine uptake in a patient with thyroid cancer and cranial metallic clips. Nuklearmedizin. 2002;41:N89–N90. [PubMed]
162. Bakheet SM, Powe J, Hammami MM. Radioiodine uptake in the chest. J Nucl Med. 1997;38:984–986. [PubMed]
163. Bakheet SM, Hammami MM, Powe J. Radioiodine uptake in rheumatoid arthritis-associated lung disease mimicking thyroid cancer metastases. Clin Nucl Med. 1998;23:319–320. [PubMed]
164. Ahn BC, Lee SW, Lee J, Kim C. Pulmonary aspergilloma mimicking metastasis from papillary thyroid cancer. Thyroid. 2011;21:555–558. [PubMed]
165. Pina JS, Meyer CA, Billingsley JL, Matlock JP, Horan MP, Knodel DH. Inflammatory diseases of the lung causing false-positive 131iodine whole body scans in the evaluation of papillary thyroid carcinoma. Two case reports. Chest. 1996;110:565–567. [PubMed]
166. Song HC, Heo YJ, Kim SM, Bom HS. Iodine-131 uptake in focal bronchiectasis mimicking metastatic thyroid cancer. Clin Nucl Med. 2003;28:351–352. [PubMed]
167. Mason DT, Frye RL, Wagner HN Jr. Radioisotope scanning of the precordial distribution of iodide in patients with myocardial infarction. Circulation. 1961;24:1338–1341. [PubMed]
168. Dreyfuss F, Ben-Porath M, Menczel J. Radioiodine uptake by the infarcted heart. Am J Cardiol. 1960;6:237–245. [PubMed]
169. Geatti O, Shapiro B, Orsolon PG, Mirolo R, Di Donna A. An unusual false-positive scan in a patient with pericardial effusion. Clin Nucl Med. 1994;19:678–682. [PubMed]
170. Lopez Aznar D, Garcia Sanchis L, Rivas Sanchez A, Alonso Monfort J, Hervas Benito I, Mateo Navarro A. [Pericardial effusion as a possible cause of false positives in I-131 radionuclide scans] . Rev Esp Med Nucl. 1998;17:158–161. [PubMed]
171. Maslack MM, Wilson CA. Iodine-131 accumulation in a pericardial effusion. J Nucl Med. 1987;28:133. [PubMed]
172. Mitchell G, Pratt BE, Vini L, McCready VR, Harmer CL. False positive 131I whole body scans in thyroid cancer. Br J Radiol. 2000;73:627–635. [PubMed]
173. Naddaf SY, Akisik MF, Omar WS, Young I, Abdel-Dayem HM. I-123 uptake in the chest wall after needle biopsy of a pulmonary nodule. A cause for false-positive I-123 uptake. Clin Nucl Med. 1997;22:572–573. [PubMed]
174. Otsuka N, Fukunaga M, Morita K, Ono S, Nagai K, Katagiri M, Harada T, Morita R. Iodine-131 uptake in a patient with thyroid cancer and rheumatoid arthritis during acupuncture treatment. Clin Nucl Med. 1990;15:29–31. [PubMed]
175. Wang PW, Chen HY, Li CH, Chen WJ. Uptake of I-131 by an abdominal neurilemoma mimicking metastatic thyroid carcinoma. Clin Nucl Med. 1993;18:964–966. [PubMed]
176. Hirata K, Shiga T, Kubota KC, Okamoto S, Kamibayashi T, Tamaki N. Radioiodine therapy for thyroid cancer depicted uterine leiomyoma. Clin Nucl Med. 2009;34:180–181. [PubMed]
177. Deandreis D, Lumbroso J, Al Ghuzlan A, Baudin E, Schlumberger M, Leboulleux S. Abnormal pelvic uptake on post-therapeutic radioiodine (131I) whole-body scan. Eur J Nucl Med Mol Imaging. 2011;38:1957. [PubMed]
178. Lakshmanan M, Reynolds JC, Del Vecchio S, Merino MJ, Norton JA, Robbins J. Pelvic radioiodine uptake in a rectal wall teratoma after thyroidectomy for papillary carcinoma. J Nucl Med. 1992;33:1848–1850. [PubMed]
179. Fernandez-Ulloa M, Maxon HR, Mehta S, Sholiton LJ. Iodine 131 uptake by primary lung adenocarcinoma. Misinterpretation of 131I scan. JAMA. 1976;236:857–858. [PubMed]
180. Langsteger W, Lind P, Koltringer P, Beham A, Eber O. Misinterpretation of iodine uptake in papillary thyroid carcinoma and primary lung adenocarcinoma. J Cancer Res Clin Oncol. 1990;116:8–12. [PubMed]
181. Langsteger W, Koltringer P, Wolf G, Eber B, Semlitsch G, Eber O. False-positive radioiodine uptake in lung carcinoma. J Nucl Med. 1994;35:2056–2057. [PubMed]
182. Misaki T, Takeuchi R, Miyamoto S, Kasagi K, Matsui Y, Konishi J. Radioiodine uptake by squamous-cell carcinoma of the lung. J Nucl Med. 1994;35:474–475. [PubMed]
183. Acosta J, Chitkara R, Khan F, Azueta V, Silver L. Radioactive iodine uptake by a large cell undifferentiated bronchogenic carcinoma. Clin Nucl Med. 1982;7:368–369. [PubMed]
184. Haubold-Reuter BG, Landolt U, von Schulthess GK. Bronchogenic carcinoma mimicking metastatic thyroid carcinoma. J Nucl Med. 1993;34:809–811. [PubMed]
185. Malhotra G, Nair N, Menon H, Gujral S, Abhyankar A, Baghel NS, Awasare S, Nabar SJ, Abhyankar S, Kand PG. Bronchoalveolar carcinoma of lung masquerading as iodine avid metastasis in a patient with minimally invasive follicular carcinoma of thyroid. Clin Nucl Med. 2008;33:26–29. [PubMed]
186. Sohn MH, Kim MW, Lim ST, Lee NR, Song EK, Yim CY. Radioiodine uptake by metastatic nonthyroidal adenocarcinoma of the lung in a patient with papillary thyroid carcinoma. Clin Nucl Med. 2005;30:269–270. [PubMed]
187. Ruel IF, Fierrard H, Vercellino L, Bernard L, Hindie E, Duron F, Toubert ME. Pulmonary metastasis of struma ovarii: a case report. Clin Nucl Med. 2010;35:692–694. [PubMed]
188. Eskin BA. Iodine and mammary cancer. Adv Exp Med Biol. 1977;91:293–304. [PubMed]
189. Wu SY, Kollin J, Coodley E, Lockyer T, Lyons KP, Moran E, Parker LN, Yu AC. I-131 total-body scan: localization of disseminated gastric adenocarcinoma. Case report and survey of the literature. J Nucl Med. 1984;25:1204–1209. [PubMed]
190. Konez O, Hanelin LG, Jenison EL, Goyal M, Randolph W. Functioning liver metastases on an I-131 whole-body scan: a case of malignant struma ovarii. Clin Nucl Med. 2000;25:465–496. [PubMed]
191. Cherng SC, Wang YF, Fan YM, Chen CY, Yuan YN, Cheng CY. Malignant struma ovarii with peritoneal implants and pelvic structures and liver metastases demonstrated by I-131 SPECT and low-dose CT. Clin Nucl Med. 2005;30:797–798. [PubMed]
192. McDougall IR. Metastatic struma ovarii: the burden of truth. Clin Nucl Med. 2006;31:321–324. [PubMed]
193. Acar E, Akgun A, Kocacelebi K, Kumanlioglu K, Tuncyurek M. I-131 uptake in malignant fibrous histiocytoma. Clin Nucl Med. 2007;32:580–581. [PubMed]
194. Lim ST, Jeong HJ, Chung MJ, Yim CY, Sohn MH. Malignant struma ovarii demonstrated on post-therapy radioiodine scan after total thyroidectomy for papillary thyroid cancer. Clin Nucl Med. 2008;33:429–431. [PubMed]
195. Kraft O, Mrhac L, Sirucek P, Dvorackova J, Chmelova J, Graf P, Sevcik L. I-131 uptake in an ovarian tumor: differential diagnosis for abdominal I-131 uptake. Clin Nucl Med. 2009;34:390–392. [PubMed]
196. McGill JF, Sturgeon C, Angelos P. Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation. Endocr Pract. 2009;15:167–173. [PubMed]
197. Ajmi S, Ben Ali K, Ben Fredj M, Ghannouchi N, Khalifa M, Letaief A. Tc-99m and I-131 uptake in widespread bone metastases from undetectable digestive adenocarcinoma. Clin Nucl Med. 2011;36:1020–1022. [PubMed]
198. Huang IC, Chou FF, Liu RT, Tung SC, Chen JF, Kuo MC, Hsieh CJ, Wang PW. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012;76:439–447. [PubMed]
199. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899. [PubMed]
200. Seifert G, Hennings K, Caselitz J. Metastatic tumors to the parotid and submandibular glands--analysis and differential diagnosis of 108 cases. Pathol Res Pract. 1986;181:684–692. [PubMed]
201. Chisholm RC, Chung EB, Tuckson W, Khan T, White JE. Follicular carcinoma of the thyroid with metastasis to the breast. J Natl Med Assoc. 1980;72:1101–1104. [PMC free article] [PubMed]
202. Cristallini EG, Ascani S, Nati S, Liberati F, Farabi R. Breast metastasis of thyroid follicular carcinoma. Acta Oncol. 1994;33:71–73. [PubMed]
203. Fiche M, Cassagnau E, Aillet G, Bailly J, Chupin M, Classe JM, Bodic MF. [Breast metastasis from a "tall cell variant" of papillary thyroid carcinoma] . Ann Pathol. 1998;18:130–132. [PubMed]
204. Kouso H, Ikegami T, Ezaki T, Ishida T, Aimitsu S, Fujihara M, Mori M. Liver metastasis from thyroid carcinoma 32 years after resection of the primary tumor: report of a case. Surg Today. 2005;35:480–482. [PubMed]
205. Shah DH, Samuel AM. Metastasis to the liver in well-differentiated carcinoma of the thyroid. Thyroid. 1996;6:607–611. [PubMed]
206. Casara D, Busnardo B, Cimitan M. Liver metastases from differentiated thyroid carcinoma. J Nucl Med Allied Sci. 1981;25:53–54. [PubMed]
207. Atmaram SH, Ganatra RD, Sharma SM, Ramanna L. Functioning metastases in liver from thyroid carcinoma: case report. J Nucl Med. 1975;16:919–921. [PubMed]
208. Oh JR, Lim JH, Jeong SY, Heo SH, Chong A, Min JJ. Simultaneous uptake of I-131 and F-18 FDG by a renal metastasis of thyroid papillary cancer. Clin Nucl Med. 2011;36:798–799. [PubMed]
209. Liou MJ, Lin JD, Chung MH, Liau CT, Hsueh C. Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol. 2005;125:438–442. [PubMed]
210. Cheon M, Choi JY, Kim HK, Chung J-H, Ko YH, Kim YE, Choi D, Lee K-H, Kim B-T. Renal metastasis from follicular thyroid carcinoma diagnosed by I-131 whole-body scan mimicking renal cell carcinoma on contrast-enhanced computed tomography. Nucl Med Mol Imaging. 2011;45:72–75.
211. Yang CW, Liang WY, Lin JK, Chiou TJ, Lee CH, Jiang JK. Colonic metastasis from a papillary thyroid carcinoma arising in struma ovarii. Int J Colorectal Dis. 2010;25:913–914. [PubMed]
212. Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and longterm outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 2006;30:1088–1095. [PubMed]
213. Caobelli F, Paghera B, Panarotto MB, Camoni L, Giubbini R. Two distant muscular metastases from papillary carcinoma of the thyroid demonstrated by 18F-FDG PET/CT and confirmed by biopsy. Nucl Med Mol Imaging. 2011;45:324–325.

Articles from American Journal of Nuclear Medicine and Molecular Imaging are provided here courtesy of e-Century Publishing Corporation